Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.
AstraZeneca will record sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within cost of sales. Daiichi Sankyo will manufacture and supply DS-1062.
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...
Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...
Verywell Health on MSN5d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeThe FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...
Read the study here. Owen and Chapman disclosed relationships with, and/or support from, UpToDate, AstraZeneca, Varian Medical Systems, Daiichi Sankyo/AstraZeneca, and the National Comprehensive ...
LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback